PharmaSGP Holding SE Logo

PharmaSGP Holding SE

Develops and markets leading natural OTC drugs for chronic conditions in the European market.

PSG | F

Overview

Corporate Details

ISIN(s):
DE000A2P4LJ5
LEI:
3912005CZ12PVVCIPT91
Country:
Germany
Address:
Lochhamer Schlag 1, 82166 Gräfelfing
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

PharmaSGP Holding SE is a pharmaceutical company specializing in the development and marketing of a broad portfolio of leading over-the-counter (OTC) drugs and other healthcare products. The company focuses on pharmacy-exclusive remedies based on natural pharmaceutical active ingredients with documented efficacy and minimal known side effects. Its core brands are market leaders in Germany and other European countries for chronic indications, including rheumatic and nerve pain (RubaXX®, Restaxil®), sleep disorders (Baldriparan®), and sexual weakness (DESEO®, NERADIN®). Since launching its first product in 2012, PharmaSGP has expanded its business model across Europe. The company's growth is driven by organic brand development and strategic acquisitions, such as its 2021 purchase of an OTC brand portfolio from GSK.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-22 15:15
Pre-Annual General Meeting Information
PharmaSGP convenes extraordinary general meeting to resolve on Squeeze-out
English 7.3 KB
2025-09-19 14:15
Report Publication Announcement
English 3.9 KB
2025-09-11 09:00
Earnings Release
PharmaSGP publishes preliminary half-year figures for 2025
English 15.7 KB
2025-08-14 12:00
Delisting Announcement
PharmaSGP Holding SE: FUTRUE GmbH, Tender of a total of 1,315 additional shares…
English 6.8 KB
2025-08-11 13:00
Delisting Announcement
PharmaSGP Holding SE: FUTRUE GmbH, Tender of a total of 39,678 additional share…
English 6.8 KB
2025-08-08 11:47
Director's Dealing
PharmaSGP Holding SE: FUTRUE GmbH, Tender of a total of 873 additional shares o…
English 6.8 KB
2025-08-07 13:11
Director's Dealing
PharmaSGP Holding SE: FUTRUE GmbH, Tender of a total of 1,505 additional shares…
English 6.8 KB
2025-08-06 16:16
Delisting Announcement
PharmaSGP Holding SE: Delisting of PharmaSGP shares from Frankfurt Stock Exchan…
English 7.8 KB
2025-08-05 10:48
Director's Dealing
PharmaSGP Holding SE: Michael Rudolf, Tender of 4,169 shares within the public …
English 5.9 KB
2025-08-04 13:58
Delisting Announcement
PharmaSGP Holding SE: Dr. Clemens Fischer, Tender of a total of 6,062 addition…
English 6.6 KB
2025-07-28 17:04
Delisting Announcement
PharmaSGP Holding SE publishes joint reasoned statement of the Management Board…
English 9.2 KB
2025-07-28 14:11
Delisting Announcement
PharmaSGP Holding SE: FUTRUE GmbH, Tender of an additional total of 4,491 share…
English 6.9 KB
2025-07-24 15:30
Director's Dealing
PharmaSGP Holding SE: FUTRUE GmbH, buy
English 6.0 KB
2025-07-24 14:11
Delisting Announcement
FUTRUE GmbH submits request to implement squeeze-out of minority shareholders o…
English 8.2 KB
2025-07-23 17:38
Declaration of Voting Results & Voting Rights Announcements
English 13.0 KB

Automate Your Workflow. Get a real-time feed of all PharmaSGP Holding SE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for PharmaSGP Holding SE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-11-25 FUTRUE GmbH Close relation Buy None 12,145,250.00 EUR
2022-10-05 MMI Leisure & Capital Management GmbH Close relation Buy None 125,383.20 EUR
2022-10-05 Hillen, Ingo Board Buy None 1,048.00 EUR
2022-10-05 MMI Leisure & Capital Management GmbH Close relation Buy None 26.60 EUR
2022-05-30 Wittig, Dr. Thomas Supervisory board Buy None 138,953.80 EUR
2022-05-30 Schröter, Jasmin Close relation Buy None 119,660.00 EUR
2022-05-30 Simon-Schröter, Dr. Wolfram Other Buy None 10,040.00 EUR
2022-04-25 FUTRUE GmbH Close relation Buy None 208,180.53 EUR
2022-04-25 MMI Leisure & Capital Management GmbH Close relation Sell None 197,193.60 EUR
2022-04-25 Bloching, Prof. Dr. Micha Supervisory board Sell None 171,825.00 EUR

Peer Companies

Company Country Ticker View
ONCODESIGN Logo
Developing precision oncology solutions for resistant and metastatic cancers.
France ALONC
Oncodesign Precision Medicine S.A Logo
Develops precision therapies & diagnostics for resistant and metastatic cancers.
France ALOPM
Oncoinvent ASA Logo
Developing alpha-emitting radiotherapies for treating cancers in the peritoneal cavity.
Norway OCIN
Oncolys BioPharma Inc. Logo
Developing oncolytic virus therapies and diagnostics for cancer and serious viral infections.
Japan 4588
Oncopeptides Logo
Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.
Sweden ONCO
Onesano S.A. Logo
Develops patented nutritional products for humans, animals, and agriculture.
Poland SKT
ONO PHARMACEUTICAL CO., LTD. Logo
Develops innovative medicines for high unmet needs in oncology, immunology, and neurology.
Japan 4528
OPKO Health Inc. Logo
Provides clinical diagnostics & develops novel therapies for serious & pediatric diseases.
Israel OPK
OPTUS Pharmaceutical Co., Ltd. Logo
Develops and manufactures ophthalmic solutions for dry eye, infections, and inflammation.
South Korea 131030
Oramed Pharmaceuticals Inc. Logo
Develops oral drug delivery systems to turn injectable drugs, like insulin, into oral therapies.
Israel ORMP

Talk to a Data Expert

Have a question? We'll get back to you promptly.